China Cord Blood Research and Development Expenses 2010-2022 | CORBF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

China Cord Blood research and development expenses from 2010 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.

China Cord Blood Research and Development Expenses 2010-2022 | CORBF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

China Cord Blood research and development expenses from 2010 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$133.5B
Elevance Health (ELV)	$96.1B
CVS Health (CVS)	$84.8B
Cencora (COR)	$55.6B
DiDi Global (DIDIY)	$20.3B
Natera (NTRA)	$20B
BioMerieux (BMXMF)	$15.6B
Solventum (SOLV)	$11.5B
ICON (ICLR)	$11.3B
EUROFINS SCIENT (ERFSF)	$11.1B
Revvity (RVTY)	$11B
CochLear (CHEOY)	$10.9B
Avantor (AVTR)	$10.3B
Doximity (DOCS)	$9.9B
Viatris (VTRS)	$9B
Medpace Holdings (MEDP)	$9B
Sonic Healthcare (SKHHY)	$7.7B
HealthEquity (HQY)	$7.3B
Charles River Laboratories (CRL)	$5.2B
Amplifon S.p.A (AMFPF)	$4.3B
Bausch + Lomb (BLCO)	$4.3B
Alignment Healthcare (ALHC)	$3.5B
Sotera Health (SHC)	$3B
BrightSpring Health Services (BTSG)	$2.9B
Organon (OGN)	$2.9B
Surgery Partners (SGRY)	$2.7B
GeneDx Holdings (WGS)	$2.7B
Concentras Parent (CON)	$2.6B
Progyny (PGNY)	$1.8B
Ardent Health Partners (ARDT)	$1.8B